Alejandra Molano-Triviño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandra Molano-Triviño has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Zuniga-Rodriguez
Department of Nephrology, La Cardio, Fundación Cardioinfantil instituto de Cardiología, Bogotá, Colombia
4 shared publications - Juan Castellanos-De la Hoz
Department of Nephrology, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia
3 shared publications Adriana Flórez
Patóloga, Fundación Santa Fe de Bogotá
1 shared publication- Alejandro Ferreiro
Universidad de la República, Uruguay
1 shared publication - Ana Milena Mejía-Sanjuanelo
Universidad del Norte, Barranquilla, Colombia
1 shared publication Benjamín Wancjer
Nefrólogo Fundación Cardioinfantil. Universidad del Rosario. Bogotá, Colombia
1 shared publication
Latest Publications
- Open Access
- 20 April 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (8) , 1884-1886
Peritoneal–Mediastinal Dialysate Leak Presenting as Chest Pain in a Patient on Peritoneal Dialysis
Peritoneal dialysis (PD)–related leaks are usually pleuroperitoneal; mediastinal extension is exceptionally rare. A 38-year-old man with ESKD due to immune complex–mediated focal segmental glomerulosclerosis on long-term automated PD presented with acute exertional chest pain mimicking an acute coronary syndrome. Cardiac biomarkers were elevated, but electrocardiography and coronary angiography showed no ischemic disease. Computed tomography pulmonary angiography excluded pulmonary embolism and revealed a paraesophageal fluid collection. Contrast-enhanced computed tomography after intraperitoneal instillation of iodinated dialysate confirmed mediastinal leakage through the esophageal hiatus. Increased intra-abdominal pressure and an umbilical hernia were identified as risk factors. PD withdrawal and transition to hemodialysis led to complete resolution. Mediastinal dialysate leakage should be considered in PD patients with unexplained chest pain; computed tomography peritoneography is diagnostic.
- 20 April 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (8) , 1884-1886
Open AccessPeritoneal–Mediastinal Dialysate Leak Presenting as Chest Pain in a Patient on Peritoneal Dialysis
Peritoneal dialysis (PD)–related leaks are usually pleuroperitoneal; mediastinal extension is exceptionally rare. A 38-year-old man with ESKD due to immune complex–mediated focal segmental glomerulosclerosis on long-term automated PD presented with acute exertional chest pain mimicking an acute coronary syndrome. Cardiac biomarkers were elevated, but electrocardiography and coronary angiography showed no ischemic disease. Computed tomography pulmonary angiography excluded pulmonary embolism and revealed a paraesophageal fluid collection. Contrast-enhanced computed tomography after intraperitoneal instillation of iodinated dialysate confirmed mediastinal leakage through the esophageal hiatus. Increased intra-abdominal pressure and an umbilical hernia were identified as risk factors. PD withdrawal and transition to hemodialysis led to complete resolution. Mediastinal dialysate leakage should be considered in PD patients with unexplained chest pain; computed tomography peritoneography is diagnostic.
- Open Access
- 14 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
From glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor
Osmotic nephropathy is an infrequent drug‑induced complication characterized by vacuolization of renal tubular cells secondary to lysosomal uptake, w
- 14 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessFrom glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor
Osmotic nephropathy is an infrequent drug‑induced complication characterized by vacuolization of renal tubular cells secondary to lysosomal uptake, w
- 9 January 2026
- Published by S. Karger AG in Blood Purification
- Vol. 55 (5) , 274-286
Extracorporeal Blood Purification Therapies in Latin America: Bridging Gaps in Availability and Training
Introduction: Socioeconomic and developmental diversity across Latin America (LA) significantly affects the availability of extracorporeal blood purification (EBP) therapies to treat acute kidney injury (AKI) and the training of nephrology fellows in these technologies. This survey assessed the availability of EBP therapies and perceived training needs of nephrologists and intensivists in the region. Objective: The aim of this study was to evaluate the availability of EBP therapies to treat AKI and identify training needs among LA nephrologists and intensivists. Methods: Between March and December 2024, the AKI and extracorporeal organ support therapy committee of SLANH conducted an online survey targeting nephrologists and intensivists. The survey gathered data on the availability of EBP technologies in their institutions and perceived training needs. Results: A total of 505 responses were collected, with 93% submitted by nephrologists. Participants represented 20 LA countries, primarily from South America (58%), Mexico (23.6%), and the Caribbean (10.1%). Intermittent hemodialysis (IHD) was the most widely available therapy, accessible in 98% of centers. Peritoneal dialysis (PD) was available in 65% of hospitals, while continuous renal replacement therapy (CRRT) in 59% of centers but reported as unavailable in Haiti, Nicaragua, Paraguay, and Venezuela. Therapeutic plasma exchange (TPE) was available in 60% of hospitals, although accessibility varied significantly by country. Multi-organ support therapies showed limited regional availability, including liver support (11.9%), extracorporeal membrane oxygenation (ECMO, 16.7%), extracorporeal CO2 removal (ECCO2R, 7%), and hemoadsorption (20.6%). The greatest perceived training needs were identified for ECMO (54.2%), ECCO2R (51.3%), CRRT (48.7%), and TPE (46.8%), whereas demand for further training in IHD and PD was comparatively lower. These findings underscore substantial disparities in therapy access and highlight urgent regional priorities for advanced EBP training. Conclusion: This study highlights significant disparities in EBP therapy availability across LA, with advanced modalities such as CRRT and multi-organ support largely inaccessible in several countries. Additionally, there is a high perceived need for training in ECMO, ECCO2R, CRRT, and TPE. Addressing these gaps requires expanding access to EBP, implementing standardized training programs, establishing regional centers of excellence, and fostering international collaboration. Policy advocacy and increased resource allocation will be essential to improving access and optimizing patient outcomes across the region.
- 9 January 2026
- Published by S. Karger AG in Blood Purification
- Vol. 55 (5) , 274-286
Extracorporeal Blood Purification Therapies in Latin America: Bridging Gaps in Availability and Training
Introduction: Socioeconomic and developmental diversity across Latin America (LA) significantly affects the availability of extracorporeal blood purification (EBP) therapies to treat acute kidney injury (AKI) and the training of nephrology fellows in these technologies. This survey assessed the availability of EBP therapies and perceived training needs of nephrologists and intensivists in the region. Objective: The aim of this study was to evaluate the availability of EBP therapies to treat AKI and identify training needs among LA nephrologists and intensivists. Methods: Between March and December 2024, the AKI and extracorporeal organ support therapy committee of SLANH conducted an online survey targeting nephrologists and intensivists. The survey gathered data on the availability of EBP technologies in their institutions and perceived training needs. Results: A total of 505 responses were collected, with 93% submitted by nephrologists. Participants represented 20 LA countries, primarily from South America (58%), Mexico (23.6%), and the Caribbean (10.1%). Intermittent hemodialysis (IHD) was the most widely available therapy, accessible in 98% of centers. Peritoneal dialysis (PD) was available in 65% of hospitals, while continuous renal replacement therapy (CRRT) in 59% of centers but reported as unavailable in Haiti, Nicaragua, Paraguay, and Venezuela. Therapeutic plasma exchange (TPE) was available in 60% of hospitals, although accessibility varied significantly by country. Multi-organ support therapies showed limited regional availability, including liver support (11.9%), extracorporeal membrane oxygenation (ECMO, 16.7%), extracorporeal CO2 removal (ECCO2R, 7%), and hemoadsorption (20.6%). The greatest perceived training needs were identified for ECMO (54.2%), ECCO2R (51.3%), CRRT (48.7%), and TPE (46.8%), whereas demand for further training in IHD and PD was comparatively lower. These findings underscore substantial disparities in therapy access and highlight urgent regional priorities for advanced EBP training. Conclusion: This study highlights significant disparities in EBP therapy availability across LA, with advanced modalities such as CRRT and multi-organ support largely inaccessible in several countries. Additionally, there is a high perceived need for training in ECMO, ECCO2R, CRRT, and TPE. Addressing these gaps requires expanding access to EBP, implementing standardized training programs, establishing regional centers of excellence, and fostering international collaboration. Policy advocacy and increased resource allocation will be essential to improving access and optimizing patient outcomes across the region.
- Open Access
- 30 October 2025
- Published by S. Karger AG in Blood Purification
- Vol. 55 (2) , 148-155
Toward Green Dialysis: Efficacy and Sustainability with Reduced Dialysate Flow in Expanded Hemodialysis
Introduction: Reducing dialysate flow (Qd) to 400 mL/min has proven to be sufficient, safe, and effective in meeting dialysis adequacy requirements in adults, with the added advantage of decreasing water consumption per dialysis session. Expanded hemodialysis (HDx), which uses dialyzers with membranes capable of enhanced clearance of medium-sized molecules due to expanded pore capacity, has higher efficiency and reduces the importance of the dialysate-to-blood flow ratio (Qd/Qb) for molecule removal. The objective of this study was to evaluate dialysis effectiveness by analyzing the reduction rate of medium-sized molecules in patients weighing ≤70 kg, comparing Qd 400 mL/min vs. 500 mL/min in HDx using Theranova® membrane. Methods: A post hoc analysis of the COREXH study population was performed. This observational, analytical, retrospective cohort study included 23 patients, of whom 11 (47%) had Qd 400 mL/min and 12 (52.1%) had Qd 500 mL/min. Results: No statistically significant differences were observed in the reduction rate of medium-sized molecules between the Qd 400 mL/min and 500 mL/min groups. Additionally, water consumption was lower in the Qd 400 mL/min group, with an average saving of 24 L per patient per session and 13,824 L over 12 weeks. Conclusion: Using Qd 400 mL/min in HDx vs. 500 mL/min did not affect dialysis effectiveness in terms of molecule reduction rates and resulted in substantial water savings in Qd 400 mL/min group.
- 30 October 2025
- Published by S. Karger AG in Blood Purification
- Vol. 55 (2) , 148-155
Open AccessToward Green Dialysis: Efficacy and Sustainability with Reduced Dialysate Flow in Expanded Hemodialysis
Introduction: Reducing dialysate flow (Qd) to 400 mL/min has proven to be sufficient, safe, and effective in meeting dialysis adequacy requirements in adults, with the added advantage of decreasing water consumption per dialysis session. Expanded hemodialysis (HDx), which uses dialyzers with membranes capable of enhanced clearance of medium-sized molecules due to expanded pore capacity, has higher efficiency and reduces the importance of the dialysate-to-blood flow ratio (Qd/Qb) for molecule removal. The objective of this study was to evaluate dialysis effectiveness by analyzing the reduction rate of medium-sized molecules in patients weighing ≤70 kg, comparing Qd 400 mL/min vs. 500 mL/min in HDx using Theranova® membrane. Methods: A post hoc analysis of the COREXH study population was performed. This observational, analytical, retrospective cohort study included 23 patients, of whom 11 (47%) had Qd 400 mL/min and 12 (52.1%) had Qd 500 mL/min. Results: No statistically significant differences were observed in the reduction rate of medium-sized molecules between the Qd 400 mL/min and 500 mL/min groups. Additionally, water consumption was lower in the Qd 400 mL/min group, with an average saving of 24 L per patient per session and 13,824 L over 12 weeks. Conclusion: Using Qd 400 mL/min in HDx vs. 500 mL/min did not affect dialysis effectiveness in terms of molecule reduction rates and resulted in substantial water savings in Qd 400 mL/min group.
- 5 November 2024
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 30 (5) , 641-648
Therapeutic plasma exchange without anticoagulation: Single‐center experience
Background: Membrane therapeutic plasma exchange (mTPE) is indicated for treating autoimmune, neurological, hematological, and renal diseases. Few studies have assessed the effectiveness and safety of this technique, especially when no anticoagulants are added. This study evaluated the outcomes of mTPE without anticoagulation at a single center.Methods: Based on registry data, this retrospective cohort study included adult patients treated with mTPE without anticoagulants for different indications.Results: From October 2021 to October 2022, 46 patients received 385 mTPE treatments. The primary diagnosis leading to the intervention was humoral rejection of the kidney transplant (59.2%). Most procedures (62.1%) were performed in the inpatient department. The complication rate was 1.3%, with 2.1% of patients experiencing device coagulation. Only five patients experienced mild adverse events. There were no cases of mortality.Conclusions: When indicated, mTPE without anticoagulation is a safe hospital technique. Protocols are needed to guide the use and monitoring of this therapy.
- 5 November 2024
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 30 (5) , 641-648
Therapeutic plasma exchange without anticoagulation: Single‐center experience
Background: Membrane therapeutic plasma exchange (mTPE) is indicated for treating autoimmune, neurological, hematological, and renal diseases. Few studies have assessed the effectiveness and safety of this technique, especially when no anticoagulants are added. This study evaluated the outcomes of mTPE without anticoagulation at a single center.Methods: Based on registry data, this retrospective cohort study included adult patients treated with mTPE without anticoagulants for different indications.Results: From October 2021 to October 2022, 46 patients received 385 mTPE treatments. The primary diagnosis leading to the intervention was humoral rejection of the kidney transplant (59.2%). Most procedures (62.1%) were performed in the inpatient department. The complication rate was 1.3%, with 2.1% of patients experiencing device coagulation. Only five patients experienced mild adverse events. There were no cases of mortality.Conclusions: When indicated, mTPE without anticoagulation is a safe hospital technique. Protocols are needed to guide the use and monitoring of this therapy.
- Open Access
- 16 February 2021
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (2) , e517
Estado del arte del síndrome cardiorrenal, ventajas y limitaciones de las terapias conocidas
Las interacciones entre las enfermedades cardíacas y renales se han clasificado como síndromes cardiorenales. La clasificación actual incluye cinco subtipos, los cuales son: insuficiencia cardíaca aguda que conduce a insuficiencia renal aguda (tipo 1), insuficiencia cardíaca crónica que conduce a insuficiencia renal (tipo 2), lesión renal aguda que conduce a insuficiencia cardíaca (tipo 3), enfermedad renal crónica que conduce a insuficiencia cardíaca (tipo 4) y afecciones sistémicas que conducen a insuficiencia cardíaca y renal (tipo 5) (Tabla 1) (1,2). En esta revisión discutimos la definición, clasificación, fisiopatología del síndrome cardiorrenal, enfocándonos en el manejo en fases agudas y su recuperación, exponiendo la evidencia actualmente disponible de los diuréticos y la ultrafiltración con el objetivo de intervenir de manera oportuna a nuestros pacientes conociendo las ventajas y limitaciones de cada una de las estrategias de manejo en aras de reducir el riesgo de eventos clínicos, re- hospitalización y muerte.
- 16 February 2021
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (2) , e517
Open AccessEstado del arte del síndrome cardiorrenal, ventajas y limitaciones de las terapias conocidas
Las interacciones entre las enfermedades cardíacas y renales se han clasificado como síndromes cardiorenales. La clasificación actual incluye cinco subtipos, los cuales son: insuficiencia cardíaca aguda que conduce a insuficiencia renal aguda (tipo 1), insuficiencia cardíaca crónica que conduce a insuficiencia renal (tipo 2), lesión renal aguda que conduce a insuficiencia cardíaca (tipo 3), enfermedad renal crónica que conduce a insuficiencia cardíaca (tipo 4) y afecciones sistémicas que conducen a insuficiencia cardíaca y renal (tipo 5) (Tabla 1) (1,2). En esta revisión discutimos la definición, clasificación, fisiopatología del síndrome cardiorrenal, enfocándonos en el manejo en fases agudas y su recuperación, exponiendo la evidencia actualmente disponible de los diuréticos y la ultrafiltración con el objetivo de intervenir de manera oportuna a nuestros pacientes conociendo las ventajas y limitaciones de cada una de las estrategias de manejo en aras de reducir el riesgo de eventos clínicos, re- hospitalización y muerte.
- Open Access
- 5 November 2020
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (1) , 155-176
Diálisis Peritoneal en tiempos difíciles.
La Diálisis Peritoneal es una terapia igual o superior a la hemodiálisis, es costo-efectiva y ha permitido el soporte dialítico vital a poblaciones víctimas de desastres naturales. En las actuales circunstancias de pandemia y aislamiento social por el COVID 19, la diálisis peritoneal, al ser una terapia domiciliaria, reduce los riesgo de exposición para pacientes, cuidadores y equipos de atención, sin embargo, es una terapia subutilizada a nivel global. Al mostrar los beneficios de la diálisis peritoneal sobre la hemodiálisis y los desenlaces de esta en tiempos de desastre, se presenta como la mejor alternativa para estos tiempos de pandemia. Se llevó a cabo una revisión no sistemática de la literatura, en busca de los beneficios de la diálisis peritoneal vs hemodiálisis y sus desenlaces en situaciones de calamidad. En esta se incluyeron 75 artículos publicados entre1993 y marzo del 2020. Estos estudios muestran los múltiples beneficios de la diálisis peritoneal sobre la hemodiálisis y ser la mejor alternativa en situaciones de desastre. Por lo anterior concluimos que la diálisis peritoneal tiene significativos beneficios sobre la hemodiálisis, entre estos una mayor supervivencia, especialmente en los dos primeros años, una menor velocidad en la tasa de perdida de la función renal residual, permite preservar los accesos vasculares, hay mayor supervivencia post trasplante, además de ser más económica y en situaciones de desastres naturales, como lo es esta pandemia, ha facilitado la continuidad de la atención y el soporte dialítico agudo o crónico para las víctimas.
- 5 November 2020
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (1) , 155-176
Open AccessDiálisis Peritoneal en tiempos difíciles.
La Diálisis Peritoneal es una terapia igual o superior a la hemodiálisis, es costo-efectiva y ha permitido el soporte dialítico vital a poblaciones víctimas de desastres naturales. En las actuales circunstancias de pandemia y aislamiento social por el COVID 19, la diálisis peritoneal, al ser una terapia domiciliaria, reduce los riesgo de exposición para pacientes, cuidadores y equipos de atención, sin embargo, es una terapia subutilizada a nivel global. Al mostrar los beneficios de la diálisis peritoneal sobre la hemodiálisis y los desenlaces de esta en tiempos de desastre, se presenta como la mejor alternativa para estos tiempos de pandemia. Se llevó a cabo una revisión no sistemática de la literatura, en busca de los beneficios de la diálisis peritoneal vs hemodiálisis y sus desenlaces en situaciones de calamidad. En esta se incluyeron 75 artículos publicados entre1993 y marzo del 2020. Estos estudios muestran los múltiples beneficios de la diálisis peritoneal sobre la hemodiálisis y ser la mejor alternativa en situaciones de desastre. Por lo anterior concluimos que la diálisis peritoneal tiene significativos beneficios sobre la hemodiálisis, entre estos una mayor supervivencia, especialmente en los dos primeros años, una menor velocidad en la tasa de perdida de la función renal residual, permite preservar los accesos vasculares, hay mayor supervivencia post trasplante, además de ser más económica y en situaciones de desastres naturales, como lo es esta pandemia, ha facilitado la continuidad de la atención y el soporte dialítico agudo o crónico para las víctimas.
- Open Access
- 5 November 2020
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (1) , e385
Hiperamonemia como causa de diálisis no renal
La hiperamonemia es una condición frecuente en pacientes cirróticos y en el contexto de una causa no cirrótica se relaciona con aumento en la producción de amonio o alteración en su eliminación. La presentación clínica de esta condición es inespecífica: va desde alteración del comportamiento hasta estado de coma, siendo una de las causas de diálisis no renal por determinados valores o refractariedad a manejo médico. Se presenta el caso de una mujer de 35 años, quien ingresó al servicio de urgencias con alteración del estado de conciencia, niveles de amonio elevados y masa hipervascular en hígado. Los estudios de aminoácidos limitantes del ciclo de la urea y ácido orótico urinario fueron normales y la biopsia de la lesión hepática reportó carcinoma hepático fibrolamelar, al cual se atribuyó la presencia de shunt portosistémico que causaba la hiperamonemia. Se indicó diálisis por persistencia de elevaciones de amonio y poca respuesta al tratamiento médico. Dada la evolución de la paciente, fue necesario reiniciar la terapia reemplazo renal por reaparición de estado encefalopático al suspender la misma. Esta terapia se mantuvo hasta el trasplante hepático que se realizó como tratamiento del carcinoma, con posterior estabilización de niveles de amonio y suspensión de la diálisis.
- 5 November 2020
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (1) , e385
Open AccessHiperamonemia como causa de diálisis no renal
La hiperamonemia es una condición frecuente en pacientes cirróticos y en el contexto de una causa no cirrótica se relaciona con aumento en la producción de amonio o alteración en su eliminación. La presentación clínica de esta condición es inespecífica: va desde alteración del comportamiento hasta estado de coma, siendo una de las causas de diálisis no renal por determinados valores o refractariedad a manejo médico. Se presenta el caso de una mujer de 35 años, quien ingresó al servicio de urgencias con alteración del estado de conciencia, niveles de amonio elevados y masa hipervascular en hígado. Los estudios de aminoácidos limitantes del ciclo de la urea y ácido orótico urinario fueron normales y la biopsia de la lesión hepática reportó carcinoma hepático fibrolamelar, al cual se atribuyó la presencia de shunt portosistémico que causaba la hiperamonemia. Se indicó diálisis por persistencia de elevaciones de amonio y poca respuesta al tratamiento médico. Dada la evolución de la paciente, fue necesario reiniciar la terapia reemplazo renal por reaparición de estado encefalopático al suspender la misma. Esta terapia se mantuvo hasta el trasplante hepático que se realizó como tratamiento del carcinoma, con posterior estabilización de niveles de amonio y suspensión de la diálisis.
- Open Access
- 1 January 2016
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 3 (1) , 52-57
Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report
Nefropatía por agente catártico basado en fosfato de sodio en paciente renal trasplantado. Reporte de un caso
- 1 January 2016
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 3 (1) , 52-57
Open AccessPhosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report
Nefropatía por agente catártico basado en fosfato de sodio en paciente renal trasplantado. Reporte de un caso